Latest Advances in Lung Cancer Research

A study developed and tested a remote intervention to improve the quality of life for lung cancer patients transitioning to post-treatment surveillance.

American Cancer Society report shows lung cancer deaths decline, boosting overall cancer survival despite persistent disparities and need for better screening.

FDA grants breakthrough designation to CLN-081, a targeted therapy for NSCLC with EGFR exon 20 mutations, showing promise in ongoing clinical trials.

Mount Sinai study shows earlier lung cancer diagnosis via CT screening significantly reduces deaths, underscoring the need for widespread screening adherence.

Rare EGFR exon insertions in lung cancer allow targeted therapies, but resistance develops; new drugs help.

[NEED EXTERNAL LINK TO ARTICLE]

Imfinzi plus chemotherapy tripled patient survival at three years in the CASPIAN Phase III trial for patients with extensive-stage SCLC.

Biomarker testing decisions for lung cancer vary by type of clinician. Fewer community oncology clinicians use biomarker testing.

Racial Disparities in Lung Cancer: Research shows racial disparities in treatment and survival between Black and White lung cancer patients.

Lack of Adherence to Treatment Guidelines for NSCLC patients was found in nearly one third of patients in a recent study.

Artificial intelligence blood test to detect lung cancer. Researchers developed novel technology to detect lung cancer in patients.

Five Year Lung Cancer Survival Update: Pembrolizumab continued to improve OS than docetaxel in patients with PD-L1 TPS ≥50% and TPS ≥1%.

Liquid biopsy simpler sampling: Liquid biopsies are easier on patients, yield faster results and cost less than tissue biopsies.